{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T10:06:18Z","timestamp":1794391578464,"version":"4.9.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000805","name":"European Centre for Disease Prevention and Control","doi-asserted-by":"publisher","award":["ECDC\/2015\/031"],"award-info":[{"award-number":["ECDC\/2015\/031"]}],"id":[{"id":"10.13039\/501100000805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vaccine.2022.05.011","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T21:31:43Z","timestamp":1653687103000},"page":"3963-3974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study"],"prefix":"10.1016","volume":"40","author":[{"given":"Camelia","family":"Savulescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavla","family":"Krizova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palle","family":"Valentiner-Branth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamez","family":"Ladhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Rinta-Kokko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolita","family":"Mereckiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Knol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brita A.","family":"Winje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Ciruela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Kozakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christian","family":"Slotved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman K.","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pekka Nuorti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Danis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didrik F.","family":"Vestrheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Munoz-Almagro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Carlos","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Castilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Colzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pastore Celentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germaine","family":"Hanquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.05.011_b0005","unstructured":"World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper \u2013February 2019. WER. 2019;94:85-103."},{"issue":"9","key":"10.1016\/j.vaccine.2022.05.011_b0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2022.05.011_b0015","unstructured":"European Medicines A. Synflorix: EPAR \u2013 Product information. Annex I - Summary of product characteristics. 2013."},{"key":"10.1016\/j.vaccine.2022.05.011_b0020","unstructured":"European Medicines A. Prevenar 13: EPAR \u2013 Product information. Annex I - Summary of product characteristics. 2014."},{"key":"10.1016\/j.vaccine.2022.05.011_b0025","unstructured":"European Medicines A. Assessment Report for Synflorix. Procedure No. EMEA\/H\/C\/000973. 2009."},{"issue":"12","key":"10.1016\/j.vaccine.2022.05.011_b0030","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/cid\/ciy920","article-title":"Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies","volume":"68","author":"Sings","year":"2019","journal-title":"Clin Infect Dis."},{"issue":"32","key":"10.1016\/j.vaccine.2022.05.011_b0035","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1016\/j.vaccine.2019.06.071","article-title":"Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006\u20132018","volume":"37","author":"Andrews","year":"2019","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2022.05.011_b0040","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.vaccine.2016.02.043","article-title":"Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule","volume":"34","author":"Weinberger","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.011_b0045","first-page":"91","article-title":"Phenotypic and genotypic characterization of serogroup 6 Streptococcus pneumoniae isolates collected during 10-valent pneumococcal conjugate vaccine era in Bulgaria","volume":"67","author":"Alexandrova","year":"2020","journal-title":"Acta Microbiol Immunol Hung"},{"key":"10.1016\/j.vaccine.2022.05.011_b0050","doi-asserted-by":"crossref","unstructured":"Naucler P, Galanis I, Morfeldt E, Darenberg J, \u00d6rtqvist \u00c5, Henriques-Normark B. Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations. Clin Infectious Dis: An Off Publication Infectious Dis Soc Am 2017;65:1780-9.","DOI":"10.1093\/cid\/cix685"},{"issue":"4","key":"10.1016\/j.vaccine.2022.05.011_b0055","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01766-18","article-title":"Vaccination of Icelandic Children with the 10-Valent Pneumococcal Vaccine Leads to a Significant Herd Effect among Adults in Iceland","volume":"57","author":"Quirk","year":"2019","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.011_b0060","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thoraxjnl-2018-211767","article-title":"Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination","volume":"74","author":"Hanquet","year":"2019","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.vaccine.2022.05.011_b0065","first-page":"648","article-title":"Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. The Lancet","volume":"5","author":"Savulescu","year":"2017","journal-title":"Respir Med"},{"issue":"48","key":"10.1016\/j.vaccine.2022.05.011_b0070","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1016\/j.vaccine.2013.07.006","article-title":"Vaccine effects and impact of vaccination programmes in post-licensure studies","volume":"31","author":"Hanquet","year":"2013","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2022.05.011_b0075","first-page":"85","article-title":"Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper \u2013 February 2019","volume":"8","author":"Publication","year":"2019","journal-title":"WER."},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.011_b0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13605-8","article-title":"External quality assurance for laboratory identification and capsular typing of streptococcus pneumoniae","volume":"7","author":"Slotved","year":"2017","journal-title":"Sci Rep."},{"issue":"10","key":"10.1016\/j.vaccine.2022.05.011_b0085","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJM198009043031003","article-title":"Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine","volume":"303","author":"Broome","year":"1980","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1016\/j.vaccine.2022.05.011_b0090","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/genes10110845","article-title":"Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader","volume":"10","author":"Groves","year":"2019","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.vaccine.2022.05.011_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028435","article-title":"Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales","volume":"6","author":"Andrews","year":"2011","journal-title":"PLoS ONE."},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.011_b0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/jpids\/piw010","article-title":"Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc."},{"issue":"39","key":"10.1016\/j.vaccine.2022.05.011_b0105","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1016\/j.vaccine.2017.08.020","article-title":"Pneumococcal vaccination: Direct and herd effect on carriage of vaccine types and antibiotic resistance in Icelandic children","volume":"35","author":"Sigurdsson","year":"2017","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2022.05.011_b0110","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1016\/j.vaccine.2009.04.009","article-title":"Estimation of vaccine efficacy against acquisition of pneumococcal carriage","volume":"27","author":"Rinta-Kokko","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.011_b0115","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4754-0","article-title":"Changes in pneumococcal carriage prevalence and factors associated with carriage in Norwegian children, four years after introduction of PCV13","volume":"20","author":"L\u00f8vlie","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.011_b0120","doi-asserted-by":"crossref","first-page":"1309504","DOI":"10.1080\/22423982.2017.1309504","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal carriage by respiratory pathogens among Greenlandic children","volume":"76","author":"Navne","year":"2017","journal-title":"Int J Circumpolar Health"},{"issue":"23","key":"10.1016\/j.vaccine.2022.05.011_b0125","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1016\/j.vaccine.2015.04.005","article-title":"Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada","volume":"33","author":"Deceuninck","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.011_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183191","article-title":"Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7\u201359 months. A matched case-control study","volume":"12","author":"Dom\u00ednguez","year":"2017","journal-title":"PLoS ONE"},{"issue":"14","key":"10.1016\/j.vaccine.2022.05.011_b0135","article-title":"to 2014: cohort and case-control study","volume":"21","author":"Guevara","year":"2016","journal-title":"Euro Surveill."},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.011_b0140","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2213-2600(16)00052-7","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study","volume":"4","author":"Moore","year":"2016","journal-title":"Lancet Respir Med."},{"issue":"4","key":"10.1016\/j.vaccine.2022.05.011_b0145","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/INF.0000000000001054","article-title":"Effectiveness of pneumococcal conjugate vaccines of different valences against invasive pneumococcal disease among children in Taiwan: a nationwide study","volume":"35","author":"Su","year":"2016","journal-title":"Pediatr Infect Dis J."},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.011_b0150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1473-3099(17)30654-0","article-title":"Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial","volume":"18","author":"Goldblatt","year":"2018","journal-title":"Lancet Infect Dis."},{"issue":"9","key":"10.1016\/j.vaccine.2022.05.011_b0155","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.2013.228052","article-title":"Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial","volume":"310","author":"Spijkerman","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.05.011_b0160","unstructured":"Savulescu C, Krizova P, Dalby T, Ladhani S, Nuorti P, Danis K, et al. Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease in European children under five years of age: SpIDnet multicentre study. European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE 2020). On-line2020."},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.011_b0165","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3201\/eid2801.210734","article-title":"Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries","volume":"28","author":"Hanquet","year":"2022","journal-title":"Europe. Emerg Infect Dis."},{"key":"10.1016\/j.vaccine.2022.05.011_b0170","doi-asserted-by":"crossref","first-page":"e0220453","DOI":"10.1371\/journal.pone.0220453","article-title":"Limited indirect effects of an infant pneumococcal vaccination program in an aging population","volume":"14","author":"van der Linden","year":"2019","journal-title":"PLoS ONE."},{"issue":"35","key":"10.1016\/j.vaccine.2022.05.011_b0175","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1016\/j.vaccine.2021.06.017","article-title":"Using genomics to examine the persistence of Streptococcus pneumoniae serotype 19A in Ireland and the emergence of a sub-clade associated with vaccine failures","volume":"39","author":"Corcoran","year":"2021","journal-title":"Vaccine."},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.011_b0180","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-2600(14)70060-8","article-title":"Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study","volume":"2","author":"Domingues","year":"2014","journal-title":"Lancet Respir Med."},{"issue":"46","key":"10.1016\/j.vaccine.2022.05.011_b0185","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1016\/j.vaccine.2015.10.007","article-title":"Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study G. Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease","volume":"33","author":"Verani","year":"2015","journal-title":"Vaccine."},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.011_b0190","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.vaccine.2019.11.049","article-title":"Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland","volume":"38","author":"Rinta-Kokko","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.011_b0195","doi-asserted-by":"crossref","first-page":"e0210081","DOI":"10.1371\/journal.pone.0210081","article-title":"Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program","volume":"14","author":"Richter","year":"2019","journal-title":"PLoS ONE"},{"issue":"13","key":"10.1016\/j.vaccine.2022.05.011_b0200","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.vaccine.2013.11.028","article-title":"Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada","volume":"32","author":"De Wals","year":"2014","journal-title":"Vaccine."},{"issue":"8","key":"10.1016\/j.vaccine.2022.05.011_b0205","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(18)30346-3","article-title":"Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach?","volume":"18","author":"Desmet","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.011_b0210","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1473-3099(20)30173-0","article-title":"Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study","volume":"21","author":"Desmet","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2022.05.011_b0215","doi-asserted-by":"crossref","first-page":"e0151125","DOI":"10.1371\/journal.pone.0151125","article-title":"Serotypes and Clonal Diversity of Streptococcus pneumoniae Causing Invasive Disease in the Era of PCV13 in Catalonia, Spain","volume":"11","author":"Del Amo","year":"2016","journal-title":"PLoS ONE."},{"issue":"12","key":"10.1016\/j.vaccine.2022.05.011_b0220","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01046-18","article-title":"Effect of Vaccination on Pneumococci Isolated from the Nasopharynx of Healthy Children and the Middle Ear of Children with Otitis Media in Iceland","volume":"56","author":"Quirk","year":"2018","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.011_b0225","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.vaccine.2020.11.044","article-title":"In-depth analysis of pneumococcal serotypes in Belgian children (2015\u20132018): Diversity, invasive disease potential, and antimicrobial susceptibility in carriage and disease","volume":"39","author":"Desmet","year":"2021","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.vaccine.2022.05.011_b0230","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.vaccine.2019.07.043","article-title":"Long-term effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae in children in Brazil","volume":"37","author":"Brandileone","year":"2019","journal-title":"Vaccine."},{"issue":"41","key":"10.1016\/j.vaccine.2022.05.011_b0235","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.011_b0240","doi-asserted-by":"crossref","first-page":"18977","DOI":"10.1038\/s41598-020-75691-5","article-title":"Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency","volume":"10","author":"L\u00f8chen","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.05.011_b0245","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12879-015-0941-9","article-title":"Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era","volume":"15","author":"van der Linden","year":"2015","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.vaccine.2022.05.011_b0250","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiz178","article-title":"Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom","author":"Kandasamy","year":"2019","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:14:11Z","timestamp":1759403651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":50,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0264410X22005813"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.011","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}